Goldman Sachs has upgraded Medtronic PLC (MDT) to Neutral from Sell, reflecting a more optimistic outlook on the company's prospects. This change may indicate improved fundamentals or increased confidence in Medtronic's strategic direction.
As of November 18, 2025, Medtronic's shares are trading at $100.80, with a market capitalization of $123.5 billion. The company, a leader in medical technology, develops and manufactures a wide range of device-based medical therapies and services. Its product categories include Advanced Surgical Technology, Cardiac Rhythm, Cardiovascular, and more.
The recent upgrade comes amid a backdrop of solid earnings performance, with Q2 2026 reporting an EPS of $1.36, surpassing expectations by 2.4%. Analysts project upcoming earnings on May 19, 2026, with an estimated EPS of $1.72 and revenue of $9.7 billion.
Analyst ratings and price targets provide valuable insights based on research and financial models. However, these assessments are based on assumptions that may not always materialize. Investors should consider multiple factors, including company fundamentals and market trends, when evaluating their options. Analyst opinions can evolve as new information becomes available, reflecting the dynamic nature of the market.